Answers are grounded in this paper and cite their sources.
Systematic review finds no compelling evidence that early treatment improves efficacy in smoldering multiple myeloma versus newly diagnosed disease, questioning premature therapy adoption.
In this systematic review of all prospective interventional clinical trials in SMM, we found significant variability in trial design, including randomization status, primary endpoints, and types of intervention used. Despite the statistical limitations, comparison of treatment regimens revealed no compelling evidence that the treatment is more effective when introduced early in SMM compared to NDMM.
No takes yet. Share an insight, caveat, or question.
Kakkilaya et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: